Noticias y Actividades de OS Therapies

OS Therapies es una empresa que cotiza bajo el símbolo de cotización OSTX (US).

Ver el organigrama con sus 11 ejecutivos principales

Biografías más buscadas en OS Therapies

• Paul Romness, Chairman of the Board and Chief Executive Officer
• Craig Eagle, Director
• Olivier Jarry, Director

Recientes movimientos de ejecutivos en OS Therapies

• Craig Eagle, se ha incorporado a la empresa como Director  (noticia publicada el 3 de julio de 2026).

Crear su alerta
para seguir los movimientos de los ejecutivos en OS Therapies.

OS Therapies tiene 2.430 competidores entre los que se incluyen Lonza (Suiza), Vertex Pharmaceuticals (Estados Unidos) y Eurofins (Luxemburgo).

Popular M&A news in Biotecnología

• Tempus has announced the acquisition of Personalis  (publicado el 20 de julio de 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado el 17 de julio de 2026).
• GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Robert Gould - Board Member en Fulcrum Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de OS Therapies

• OS Therapies to Spinoff OS Animal Health into Standalone Public Company
• OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
• OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
• OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
• Press Releases
• OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
• OS Therapies to Participate in Fall 2025 Conferences and Events
• OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
• OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
• OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
• View more press releases Close

Redes sociales sobre OS Therapies

• OS Therapies en Wikipedia, Google News y Yahoo Finance
• OS Therapies en LinkedIn, Twitter y YouTube